Outset Medical Q3 2026 Earnings Conference Call - OUTSET MEDICAL INC

Financial Performance:

• Q3 2026 total revenue reached $33.6 million, representing a 14% year-over-year (YoY) increase and 6% sequential growth.
• Product revenue was $23.7 million (+15% YoY), with console revenue specifically growing 26% YoY to $10.5 million.
• Consumable revenue was $13.2 million (+8% YoY), while service and other revenue was $9.9 million (+12% YoY).
• Recurring revenue (consumables + services) totaled $23.1 million, up 10% YoY.
• Non-GAAP gross margin improved to 40.8% (up 100 bps YoY), driven by product cost reductions and service efficiencies; product margin was 44.2% (-150 bps YoY) due to console mix, while service margin was 32.4% (+760 bps YoY) due to higher EMR attachment.
• Non-GAAP operating expenses were $24.2 million (excluding $1M bad debt), reflecting only a 4% increase against 14% revenue growth (300 bps operating leverage).
• Non-GAAP net loss was $12.9 million; cash and equivalents stood at $140.7 million with quarterly cash burn of $10.3 million.
• Cumulative retention rate among parent customers who purchased consoles is 96% since commercial launch.

Guidance and Future Outlook:

• Reiterated full-year 2026 revenue guidance of $125 million to $130 million.
• Full-year non-GAAP gross margin guidance remains in the low 40% to mid-40% range, noting a potential shift lower due to higher console sales mix.
• Full-year cash burn is projected at approximately $40 million.
• Management aims to return to double-digit annual growth in 2027, though specific 2027 revenue guidance was deferred to the Q4 report.
• Long-term capital spending environment for customers remains stable with no perceived slowdown.

Business Segments and Product Lines:

• Console Growth Drivers: Strategy focuses on three pillars: refresh ($150M estimated opportunity over ~3,000 consoles), expansion (same-store and new facilities), and new customer acquisition.
• Refresh Strategy: Secured first significant refresh agreement with HCA; actively engaging large health systems as consoles near end-of-life.
• Expansion: 14 of the largest health systems by console opportunity are existing customers; Tableau is in ~50% of the top 100 IVNs.
• Commercial Model Evolution: Reducing territory sizes for deeper relationships, realigning compensation incentives, and expanding the capital sales team at national account levels.
• Product Ecosystem: Tableau ecosystem now comprises over 10 trillion data points; EMR offering growth accelerated (+23% YoY).
• Next-Gen System: Preparation for full release is ongoing with a priority on high-quality customer experience over speed; expected to scale in coming months.

Market and Competitive Landscape:

• Policy Tailwinds: HHS launched the Kidney Care National Plan promoting patient choice, home dialysis expansion, and reduced barriers for new entrants.
• Market Dynamics: Health systems under cost pressure are increasingly adopting in-source dialysis; Outset is the clear technology leader.
• Customer Advocacy: Outset achieved customer satisfaction scores exceeding third-party healthcare benchmarks; high value placed on timely dialysis, lower infrastructure burden, and simplified nurse training.
• Target Accounts: Commercial focus remains on the top 250 Integrated Delivery Networks (IDNs) to capture the largest TAM.

Risks and Challenges:

• Policy Implementation: The ultimate impact of the HHS National Plan depends on specific implementation details and regulatory timelines.
• Margin Mix: Higher volume of one-time console sales may compress overall gross margins toward the lower end of the guidance range.
• Execution Risk: Successfully transitioning from individual site success to system-wide adoption and managing large-scale national account rollouts.
• Macro Environment: Dependence on capital spending discipline within the healthcare sector, though currently no major shifts detected.

Management Commentary and Tone:

• Tone: Highly confident and execution-focused; management emphasized "solid progress," "foundational work," and being "well-positioned" to capture market opportunity.
• Strategy: Management highlighted the alignment of clinical excellence, data analytics, and commercial execution to drive predictable, profitable growth.
• Validation: Cited the 96% customer retention rate and HHS policy support as validation of the business model and market timing.

Analyst Questions and Answers:

• Home Dialysis Outlook (Q: Josh Jennings, TD Cowen): Leslie Trigg noted the HHS plan is a positive tailwind for home dialysis adoption. Key metrics include industry-leading patient training speed and a 90-day retention rate of >90%, which predicts long-term success. Growth is driven by deepening patient census in existing home programs and partnerships with large MDOs.
• Acute Setting & Next-Gen (Q: Josh Jennings, TD Cowen): Management confirmed next-gen system development is on track with a focus on quality and customer experience. The acute strategy targets refresh, expansion, and new acquisition within the top 250 IDNs.
• Guidance & 2027 Outlook (Q: Kendall Al, RBC Capital Markets): Rene Gaeta explained that guidance was not raised to maintain discipline and ensure the company sets itself up for success, noting the back-half of 2026 is already aggressive. Confirmed intent to return to double-digit growth in 2027; no specific 2027 revenue number provided yet.
• CapEx Environment (Q: Kendall Al, RBC Capital Markets): No significant changes in customer capital spending climate are anticipated heading into 2027.

Other Key Points:

• Outset has completed over 4 million cumulative dialysis treatments using Tableau.
• Four of the top 10 U.S. health systems completed new go-live implementations this quarter.
• The clinical excellence team utilizes a customized project plan for hospital transitions, covering nurse training, physician education, and change management.
• Sales team is actively converting "white space" opportunities among hospitals that have not yet adopted Tableau.